Skip to main content
SpringerLink
Log in

Improving Adverse Drug Reaction Monitoring

  • Leading Article
  • Published:
Medical Toxicology and Adverse Drug Experience Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • ADRAC (Australian Adverse Drug Reactions Advisory Committee). Mianserin: a possible cause of neutropenia and agranulocytosis. Medical Journal of Australia 2: 673, 1980

    Google Scholar 

  • ADRAC. Prazosin hydrochloride and urinary incontinence. Australian Adverse Drug Reactions Bulletin, September 1983

  • ADRAC. Moduretic hyponatraemia. Australian Adverse Drug Reactions Bulletin, November 1984

  • Editorial. Improving reports of adverse drug reactions. British Medical Journal 289: 898, 1984

  • Edwards IR. Adverse drug reaction monitoring: the practicalities. Medical Toxicology 2: 405–410, 1987

    PubMed  CAS  Google Scholar 

  • Farrell G, et al. Halothane hepatitis: detection of a constitutional susceptibility factor. New England Journal of Medicine 313: 1310, 1985

    Article  PubMed  CAS  Google Scholar 

  • Goulston SJM. Immediate reactions to measles vaccine: comment by ADEC — and a request for information. Medical Journal of Australia 2: 313, 1981

    Google Scholar 

  • Henry DA. The Industries Assistance Commission Draft Report on Pharmaceutical Products. The likely impact on drug regulation in Australia. Medical Journal of Australia 144: 256, 1986a

    Google Scholar 

  • Henry DA. NSAIDs: do they really cause upper gastrointestinal haemorrhage? (editorial). Current Therapeutics 27(5): 13–17, 1986b

    Google Scholar 

  • Henry DA, et al. Glucomannan and risk of oesophageal obstruction. British Medical Journal 292: 591, 1985

    Article  Google Scholar 

  • Inman WHW. Let’s get our act together. In Dukes MNG (Ed.) Side Effects of Drugs Annual 9, pp. xv–xxiii, Elsevier, Amsterdam, 1985

    Google Scholar 

  • Inman WHW. Requirements for risk-benefit assessment of drugs before withdrawal. British Institute of Regulatory Affairs Journal 5(2): 11–15, 1986

    Google Scholar 

  • Inman WHW, Rawson NSB. Peptic ulcer and piroxicam. British Medical Journal 290: 932–933, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lasagna L. Discussion of paper by Dukes MNG. The epidemiology of adverse reactions. In Bostrom & Ljungstedt (Eds). Detection and prevention of adverse drug reactions, pp. 15–30, Almqvist & Wiskell International, Stockholm, 1984

    Google Scholar 

  • Maclay WP, Crowder D, Spiro S, Turner P. Postmarketing surveillance: practical experience with ketotifen. British Medical Journal 288: 911–914, 1984

    Article  PubMed  CAS  Google Scholar 

  • McEwen J. Phenylpropanolamine-associated hypertension after the use of ‘over-the-counter’ appetite-suppressant products. Medical Journal of Australia 2: 71, 1983a

    PubMed  CAS  Google Scholar 

  • McEwen J. Early-onset reaction after measles vaccination: further Australian reports. Medical Journal of Australia 2: 503, 1983b

    PubMed  CAS  Google Scholar 

  • McEwen J, Meyboom RHB. Testicular pain caused by mazindol. British Medical Journal 287: 1763, 1983

    Article  PubMed  CAS  Google Scholar 

  • McEwen J, Strickland WJ. Mebhydrolin napadisylate: a possible cause of reversible agranulocytosis and neutropenia. Medical Journal of Australia 2: 523, 1983

    Google Scholar 

  • Mashford ML. Australia. In Inman WHW (Ed.) Monitoring for Drug Safety, pp. 49–57, MTP Press Limited, Lancaster, 1986

    Google Scholar 

  • Morse ML. The Compass data base. Drug Information Journal 19: 249–252, 1985

    Google Scholar 

  • Olsson S, et al. Photosensitivity during treatment with azapropazone. British Medical Journal 291: 939, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rossi AC, Knapp DE, Anello C, O’Neill RT, Graham CF, Mendelis PS, et al. Discovery of adverse drug reactions: a comparison of selected Phase IV studies with spontaneous reporting methods. Journal of the American Medical Association 249: 2226–2228, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sheffield LJ, Batagol R. The creation of therapeutic orphans — or, what have we learnt from the Debendox fiasco? Medical Journal of Australia 143: 143, 1985

    PubMed  CAS  Google Scholar 

  • Stricker BHCh, et al. Acute hypersensitivity reactions to paracetamol. British Medical Journal 291: 938, 1985

    Article  PubMed  CAS  Google Scholar 

  • Venning GR. Identification of adverse reactions to new drugs. Part III: Alerting processes and early warning systems. British Medical Journal 286: 458–460, 1983a

    Article  PubMed  CAS  Google Scholar 

  • Venning GR. Identification of adverse reactions to new drugs. Part IV: Verification of suspected adverse reactions. British Medical Journal 286: 544–547, 1983b

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adverse Drug Reactions Advisory Committee, Canberra, Australia

    John McEwen (Secretary)

Authors
  1. John McEwen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McEwen, J. Improving Adverse Drug Reaction Monitoring. Med Toxicol Adverse Drug Exp 2, 398–404 (1987). https://doi.org/10.1007/BF03259874

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259874

Keywords

Search

Navigation